Everlywell Shark Tank Update 2026: From $1M Deal to a $3.5B Digital Health Empire

Everlywell is a digital health company that provides consumers with access to at-home lab tests with results reviewed by board-certified physicians. By removing the friction of scheduling doctor appointments and visiting laboratories, the brand has revolutionized the diagnostic experience.

Since appearing on Shark Tank, the company has expanded its reach to millions of households and successfully transitioned into its parent organization, Everly Health. With massive retail partnerships and a valuation that puts it among the show’s top success stories, Everlywell is no longer just a startup—it’s a healthcare mainstay.

Let’s break it down.

What Is Everlywell?

Everlywell offers a suite of validated at-home lab tests that allow users to collect their own samples (typically via finger-prick blood, saliva, or urine) and mail them to certified laboratories. Each test includes a digital report that is easy to read and includes physician oversight for every result.

The company differentiates itself by focusing on “biomarker intelligence,” using AI to help consumers understand their results and navigate potential next steps in their care.

Key Product Categories:

• General Wellness: Food Sensitivity, Metabolism, and Thyroid tests.
• Nutritional Health: Vitamin D, B12, and Omega-3 screenings.
• Women’s & Men’s Health: Fertility, Testosterone, and Perimenopause panels.
• Specialized Screening: HbA1c (diabetes), Heart Health, and Sexual Health (STDs).
• Advanced Clinical: Multi-cancer early detection (MCED) and gut microbiome analysis.

Founders & Background

Everlywell was founded by Julia Cheek, who serves as the CEO of the parent company, Everly Health. Cheek holds an MBA from Harvard Business School and had a background in corporate strategy before venturing into the world of healthcare.

The idea for Everlywell originated from Cheek’s own frustrating experience with the healthcare system. After suffering from unexplained fatigue and muscle pain, she spent months visiting various specialists and paid thousands of dollars out-of-pocket for lab tests that were never clearly explained to her.

Motivated by this lack of transparency and high costs, she launched Everlywell in 2015 to empower people with their own health data. Early challenges included navigating complex medical regulations and convincing the healthcare industry that consumers could reliably collect their own samples at home.

Shark Tank Pitch

Julia Cheek appeared on Shark Tank in 2017 during Season 9. She entered the tank seeking an investment to help scale the company’s logistics and marketing efforts.

• Year / Season: 2017 / Season 9
• Ask: $1 million for 5% equity
• Final Deal: $1 million line of credit at 8% interest for 5% equity
• Investing Shark: Lori Greiner

The pitch was intense, with several sharks expressing concern about the high valuation and the competitive nature of the medical testing industry. However, Lori Greiner saw the potential for a massive disruption in the consumer healthcare space. The deal was structured as a line of credit to provide the company with the necessary capital to scale without diluting the founder too heavily at a critical growth stage.

What Happened After Shark Tank?

The “Shark Tank Effect” was immediate, leading to a massive spike in sales and brand awareness. With Lori Greiner’s backing, Everlywell shifted from a purely direct-to-consumer (DTC) model to a massive retail presence.

By 2021, the company rebranded as Everly Health after acquiring PWNHealth and Home Access Health Corp, which allowed them to offer end-to-end clinical oversight. During the COVID-19 pandemic, Everlywell became a household name by providing some of the first FDA-authorized at-home collection kits for the virus.

In 2025 and 2026, the company expanded into high-stakes clinical areas like cancer screening and AI-driven health monitoring through its “Everlywell 360” subscription and “Eva” AI platform.

Financial Milestones

Everlywell’s financial trajectory has been one of the most aggressive in the history of the show.

• 2017: Secured $1 million deal on Shark Tank with $2.50 million in annual revenue.
• 2019: Raised $50 million in Series C funding to expand retail operations.
• 2020: Achieved “Unicorn” status with a $1.30 billion valuation after a $175 million Series D round.
• 2021: Reached a valuation of $2.90 billion following major acquisitions.
• 2024: Surpassed $1.10 billion in total lifetime sales.
• 2025: Secured a $595 million legal settlement with Walgreens over a contract dispute.

Revenue, Sales & Net Worth (2026)

As of 2026, Everly Health remains a private company, but its financial performance is closely tracked by analysts.

• Lifetime Revenue: Over $1.20 billion.
• Annual Revenue (2025/2026): Estimated between $100 million and $250 million ARR (Annual Recurring Revenue).
• Estimated Valuation (2026): Approximately $3.56 billion.
• Total Funding Raised: ~$674 million.

Product & Market

Everlywell occupies a premium position in the at-home diagnostic market, controlling approximately 30.00% of the U.S. consumer market. Their target audience includes health-conscious Gen X and Millennial consumers who value convenience and proactive wellness.

The company’s competitive advantage lies in its “closed-loop” system, which provides not just lab results, but also physician reviews and telehealth consultations. In 2026, the company launched “Caris Detect,” a multi-cancer early detection blood test that significantly expanded its clinical footprint.

Where to Buy

• Official Website: Everlywell.com
• Online Marketplaces: Amazon, FSA Store, and HSA Store.
• Retail Presence: Available nationwide at CVS, Walgreens, Target, Walmart, and Kroger.

Growth Breakdown: Why It Succeeded

Everlywell’s success is driven by a masterclass in business model evolution. While many Shark Tank companies struggle to move beyond a single product, Julia Cheek built a platform.

The business succeeded by focusing on branding—making clinical tests feel like a modern consumer product. By securing high-profile distribution partnerships with retailers like Target and CVS, they moved past the limitations of digital-only marketing. Furthermore, their B2B strategy—selling tests to insurance companies and large employers—now accounts for nearly 40.00% of their revenue, providing long-term stability.

Current Status (2026)

Everlywell is very much still in business and is currently in a phase of steady growth. Under the parent organization Everly Health, the brand is no longer just a “kit company” but a comprehensive digital care platform.

In early 2026, the company partnered with Caris Life Sciences to launch advanced cancer screening technology to the general public. While Lori Greiner reportedly exited her direct investment in May 2025, she remains a prominent advocate and spokesperson for the brand’s 2026 health initiatives.

Quick Summary Table

• Founded: 2015
• Founders: Julia Cheek
• Shark: Lori Greiner
• Deal: $1M Line of Credit for 5% Equity
• Revenue: $100M - $250M ARR (2026)
• Status: Active & Growing

Final Thoughts

Everlywell is more than just a Shark Tank success story; it is a case study in how to disrupt a legacy industry. By putting diagnostic data directly into the hands of consumers, Julia Cheek didn’t just sell a product—she changed how people interact with the healthcare system.

The key lesson for entrepreneurs here is the power of the pivot. Everlywell’s transition from a DTC startup to a B2B healthcare infrastructure provider allowed it to scale to a multi-billion dollar valuation where other testing companies failed. As they look toward a potential IPO in late 2026 or 2027, Everlywell remains the gold standard for what a Shark Tank investment can become.